Psoriasis

March 18, 2021

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

November 27, 2019

Children with inflammatory bowel disease, juvenile idiopathic arthritis, and chronic noninfectious osteomyelitis who were treated with TNF inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, say researchers recently writing in Arthritis Care & Research.

July 15, 2019

Patients with severe psoriasis are also at a significant increase for developing advanced liver fibrosis, new research shows

May 30, 2019

Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results.

February 26, 2019

Biological therapies prescribed for rheumatic diseases may also reduce their long-term risks of cardiovascular diseases (CVD), new research shows.

February 13, 2019

A new study in JAMA Dermatology raises an interesting question for physicians who treat psoriasis patients. Does methotrexate work best in patients with plaque psoriasis alone or patients who have both psoriasis and arthritis?

January 29, 2019

January 29, 2019

Online care and in-person care are equally effective at improving psoriasis symptoms, shows a study published in JAMA Network Open.

January 23, 2019

(1) Inflammatory diseases raise risk of venous thromboembolism; (2) antiphospholipid antibodies play a role in MI; (3) persistent hyperuricemia predicts mortality.